ICOS

Overview

ICOS (Inducible T-Cell Co-Stimulator) encodes a co-stimulatory receptor on activated T cells that is structurally related to CD28 and CTLA-4. In the cancer immunotherapy context, ICOS is upregulated on-therapy in response to anti-PD-1 treatment in melanoma and has been nominated as a candidate target for combination immunotherapy strategies.

Alterations observed in the corpus

  • Upregulated on-therapy following nivolumab treatment in advanced melanoma; upregulation observed in all patients (not restricted to responders). Nominated as a candidate combination immunotherapy target. PMID:29033130

Cancer types (linked)

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • Nominated as a candidate target for combination immunotherapy regimens with anti-PD-1 agents, based on on-therapy upregulation in advanced melanoma. PMID:29033130

Open questions

  • ICOS upregulation was observed in all patients (responders and non-responders), limiting its utility as a predictive biomarker in isolation; combination strategies require prospective testing. PMID:29033130

Sources

This page was processed by crosslinker on 2026-05-15.